Winners / 2024

Novel Dual-Targeted Therapy for Glaucoma

By: Industrial Technology Research Institute (ITRI)
Gold

Master Category:

Award Category: Health, Medical & Biotech

Award Sub-Category: Cardiovascular & Ophthalmic Innovations

Glaucoma is the second leading cause of blindness. Revolutionary glaucoma drug ITRI-E-(S)4046, administered in eye drops, lowers intraocular pressure three times more than current medication by targeting two enzymes simultaneously. Unlike conventional drugs, this treatment requires just one application per day, reducing side effects.

Explore more Health & Wellness

Put your innovation in the spotlight.

For four decades, the Edison Awards have recognized innovative products, services, and technologies that create meaningful value and impact. Explore the categories, find the right fit, and enter your new innovation for recognition.

Ready for Nomination Season?

Complete the form below to download the 2027 Nomination Guide.

A Founders Guide to Modern Innovation
The Future of the Grid – Panel Discussion 2024 Edison Awards
Edison Award-Winning Brain Technology Featured in U.S. News & World Report